Cellectis (CLLS) to Release Quarterly Earnings on Wednesday

Cellectis (NASDAQ:CLLS) is anticipated to announce its Q4 2025 results before the market opens on Wednesday, March 11th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $10.74 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 10, 2026 at 4:00 AM ET.

Cellectis Stock Up 2.5%

NASDAQ:CLLS opened at $3.75 on Thursday. The business’s 50-day simple moving average is $4.11 and its two-hundred day simple moving average is $3.86. Cellectis has a 52 week low of $1.10 and a 52 week high of $5.48. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.49 and a quick ratio of 1.49.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Global Retirement Partners LLC bought a new position in shares of Cellectis during the fourth quarter valued at approximately $34,000. Virtu Financial LLC purchased a new stake in Cellectis in the third quarter worth $72,000. Acadian Asset Management LLC increased its stake in Cellectis by 132.9% in the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 26,461 shares during the period. Millennium Management LLC lifted its position in shares of Cellectis by 61.9% during the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 22,080 shares during the last quarter. Finally, Marshall Wace LLP boosted its position in Cellectis by 1,610.3% in the 4th quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock valued at $864,000 after buying an additional 168,038 shares during the period. Hedge funds and other institutional investors own 63.90% of the company’s stock.

Analyst Upgrades and Downgrades

CLLS has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a research note on Wednesday, January 21st. Clear Str raised Cellectis to a “strong-buy” rating in a research note on Tuesday, December 23rd. Finally, Jefferies Financial Group began coverage on Cellectis in a report on Tuesday, February 17th. They set a “buy” rating and a $7.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Cellectis currently has an average rating of “Moderate Buy” and an average target price of $6.33.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.